184
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects*

, , , , , , , , & show all
Pages 1813-1823 | Accepted 07 Jul 2006, Published online: 11 Aug 2006

References

  • Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736–43
  • Wardlaw JM, Sandercock PAG, Warlow CP, Lindley RI. Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter? Stroke 2000;31:1133–5
  • Adams Jr HP, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056–83
  • Green AR, Ashwood T, Odergren T, Jackson DM. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 2003;100: 195–214
  • Kuroda S, Tsuchidate R, Smith ML, et al. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778–87
  • Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190–8
  • Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103–12
  • Marshall JWB, Cummings RM, Bowes LJ, et al. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003;34:2228–33
  • Edenius C, Strid S, Borga O, et al. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis 2002;11:34–43
  • Strid S, Borga O, Edenius C, et al. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002;58:409–15
  • Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32:675–80
  • Lees KR, Barer D, Ford GA, et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482–7
  • Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. New Engl J Med 2006;354:588–600
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
  • Jakobsen JA, Nossen JO, Jorgensen NP, Berg KJ. Renal tubular effects of diuretics and X-ray contrast media. A comparative study of equimolar doses in healthy volunteers. Invest Radiol 1993;28:319–24
  • Jung K. Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction. Kidney Int Suppl 1994;47:S29–S33
  • Murakami R, Tajima H, Kumazaki T. Effect of iomeprol on renal function immediately after abdominal angiography. Acta Radiol 1996;37:962–5
  • Lehman EL. Nonparametrics: statistical methods based on ranks. Prentice Hall; 1998. pp 232–5
  • Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf J 1995;29:1039–48

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.